Literature DB >> 29860503

Choice of binding sites for CTCFL compared to CTCF is driven by chromatin and by sequence preference.

Philipp Bergmaier1, Oliver Weth1, Sven Dienstbach1, Thomas Boettger2, Niels Galjart3, Marco Mernberger4, Marek Bartkuhn1, Rainer Renkawitz1.   

Abstract

The two paralogous zinc finger factors CTCF and CTCFL differ in expression such that CTCF is ubiquitously expressed, whereas CTCFL is found during spermatogenesis and in some cancer types in addition to other cell types. Both factors share the highly conserved DNA binding domain and are bound to DNA sequences with an identical consensus. In contrast, both factors differ substantially in the number of bound sites in the genome. Here, we addressed the molecular features for this binding specificity. In contrast to CTCF we found CTCFL highly enriched at 'open' chromatin marked by H3K27 acetylation, H3K4 di- and trimethylation, H3K79 dimethylation and H3K9 acetylation plus the histone variant H2A.Z. CTCFL is enriched at transcriptional start sites and regions bound by transcription factors. Consequently, genes deregulated by CTCFL are highly cell specific. In addition to a chromatin-driven choice of binding sites, we determined nucleotide positions critical for DNA binding by CTCFL, but not by CTCF.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29860503      PMCID: PMC6101590          DOI: 10.1093/nar/gky483

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  52 in total

Review 1.  BORIS in human cancers -- a review.

Authors:  Irena Martin-Kleiner
Journal:  Eur J Cancer       Date:  2011-10-21       Impact factor: 9.162

2.  The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.

Authors:  Michele Zampieri; Fabio Ciccarone; Rocco Palermo; Samantha Cialfi; Claudio Passananti; Sabina Chiaretti; Daniela Nocchia; Claudio Talora; Isabella Screpanti; Paola Caiafa
Journal:  Biochim Biophys Acta       Date:  2014-06-28

3.  Genomic discovery of potent chromatin insulators for human gene therapy.

Authors:  Mingdong Liu; Matthew T Maurano; Hao Wang; Heyuan Qi; Chao-Zhong Song; Patrick A Navas; David W Emery; John A Stamatoyannopoulos; George Stamatoyannopoulos
Journal:  Nat Biotechnol       Date:  2015-01-12       Impact factor: 54.908

4.  Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells.

Authors:  Jessica Zuin; Jesse R Dixon; Michael I J A van der Reijden; Zhen Ye; Petros Kolovos; Rutger W W Brouwer; Mariëtte P C van de Corput; Harmen J G van de Werken; Tobias A Knoch; Wilfred F J van IJcken; Frank G Grosveld; Bing Ren; Kerstin S Wendt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-13       Impact factor: 11.205

5.  Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.

Authors:  Koji Okabayashi; Tomonobu Fujita; Junichiro Miyazaki; Tsutomu Okada; Takashi Iwata; Nobumaru Hirao; Shinobu Noji; Nobuo Tsukamoto; Naoki Goshima; Hirotoshi Hasegawa; Hiroya Takeuchi; Masakazu Ueda; Yuko Kitagawa; Yutaka Kawakami
Journal:  Cancer Sci       Date:  2012-07-16       Impact factor: 6.716

6.  De novo prediction of DNA-binding specificities for Cys2His2 zinc finger proteins.

Authors:  Anton V Persikov; Mona Singh
Journal:  Nucleic Acids Res       Date:  2013-10-03       Impact factor: 16.971

7.  The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.

Authors:  Jessamy C Tiffen; Charles G Bailey; Amy D Marshall; Cynthia Metierre; Yue Feng; Qian Wang; Sarah L Watson; Jeff Holst; John E J Rasko
Journal:  Int J Cancer       Date:  2013-05-02       Impact factor: 7.396

8.  Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.

Authors:  Loredana Alberti; Lorena Losi; Serge Leyvraz; Jean Benhattar
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

9.  The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.

Authors:  Elena M Pugacheva; Evgeny Teplyakov; Qiongfang Wu; Jingjing Li; Cheng Chen; Chengcheng Meng; Jian Liu; Susan Robinson; Dmitry Loukinov; Abdelhalim Boukaba; Andrew Paul Hutchins; Victor Lobanenkov; Alexander Strunnikov
Journal:  Epigenetics Chromatin       Date:  2016-08-31       Impact factor: 4.954

10.  Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.

Authors:  Elena M Pugacheva; Samuel Rivero-Hinojosa; Celso A Espinoza; Claudia Fabiola Méndez-Catalá; Sungyun Kang; Teruhiko Suzuki; Natsuki Kosaka-Suzuki; Susan Robinson; Vijayaraj Nagarajan; Zhen Ye; Abdelhalim Boukaba; John E J Rasko; Alexander V Strunnikov; Dmitri Loukinov; Bing Ren; Victor V Lobanenkov
Journal:  Genome Biol       Date:  2015-08-14       Impact factor: 13.583

View more
  6 in total

1.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

Review 2.  One protein to rule them all: The role of CCCTC-binding factor in shaping human genome in health and disease.

Authors:  Michal Lazniewski; Wayne K Dawson; Anna Maria Rusek; Dariusz Plewczynski
Journal:  Semin Cell Dev Biol       Date:  2018-10-11       Impact factor: 7.727

Review 3.  CTCF and CTCFL in cancer.

Authors:  Roxanne E Debaugny; Jane A Skok
Journal:  Curr Opin Genet Dev       Date:  2020-04-22       Impact factor: 5.578

4.  BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.

Authors:  Joanna C Hillman; Elena M Pugacheva; Carter J Barger; Sirinapa Sribenja; Spencer Rosario; Mustafa Albahrani; Alexander M Truskinovsky; Aimee Stablewski; Song Liu; Dmitri I Loukinov; Gabriel E Zentner; Victor V Lobanenkov; Adam R Karpf; Michael J Higgins
Journal:  Mol Cancer Res       Date:  2019-07-10       Impact factor: 6.333

5.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

6.  Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation.

Authors:  Mayilaadumveettil Nishana; Caryn Ha; Javier Rodriguez-Hernaez; Ali Ranjbaran; Erica Chio; Elphege P Nora; Sana B Badri; Andreas Kloetgen; Benoit G Bruneau; Aristotelis Tsirigos; Jane A Skok
Journal:  Genome Biol       Date:  2020-05-11       Impact factor: 13.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.